Who
Mark Bachleda
Director
Company insider
Files Form 4 as: Director, Lyell Immunopharma; Chief Commercial Officer, Galera Therapeutics.
In numbers
- Trades disclosed
- 7
- Buys
- 1
- Sells
- 0
- Bought
- $25K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 8 Oct 2021
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,250 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,250 at $0.00 | filing |
| 9 Jun 2025filed 11 Jun 2025 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 16 Mar 2023filed 20 Mar 2023 | Galera TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K11,000 at $2.25 | filing |
| 25 Feb 2023filed 28 Feb 2023 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 28 Feb 2022filed 2 Mar 2022 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 8 Oct 2021filed 12 Oct 2021 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.